We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tek Antipsikotik ve Çoklu Antipsikotik Alan Şizofreni Hastalarında Metabolik Sendrom Sıklığı ve İlişkili Etmenler.
- Authors
Öncü, Fatih; Acuner, Tufan T.; Atalar, Fatmahan; Türkcan, Solmaz; Yeşilbursa, Doğan; Uygur, Niyazi
- Abstract
Metabolic syndrome and related factors treated with antipsychotics monotherapy and polypharmacy in patients with schizophrenia Objective: The aim of our study was to determine the prevalence of MetS and to investigate related factors in the group of inpatients with schizophrenia treated with antipsychotics monotherapy (AM) and polypharmacy (AP). Methods: Inpatients with schizophrenia(n:71) treated with antipsychotic were included in this study and a comparison was made among AM(n:19) and AP(n:52). The demographic and clinical data of patients were recorded. Blood samples were collected. Fasting blood glucose(FBG), total cholesterol, triglyceride and HDL were measured. The waist circumference, weight and height were also measured. Body mass index(BMI) was calculated for all patients. In our study, the criteria of MetS, as proposed by the International Diabetes Federation(IDF), were used. Results: Although the total duration of the hospitalization of AP was longer, there was no significant statistical difference from another group. In AP group(23,54±29,65 months, 1103,25±351,90 mg/day), the medicine usage duration and the equivalent dose of chlorpromazine was higher than AM group(5,11±6,84 months, 414,95±222,88 mg/day). There was no statistical significant difference among two groups according to FBG, total cholesterol, triglyceride, HDL, BMI, waist circumference and weight average. However, the higher obesity(90,4% vs 63,2%) ratio was determined in the AP group. According to standarts of IDF, the prevalence of MetS was found 21,2% in the AP group and 31,6% in the other group. No statistical difference of any significance was observed. Conclusion: Although the medicine usage, dose and duration of AP group were significantly longer, the ratio of MetS in this group is lower than AM group. We did not find any statistical significance difference. It was observed that AP group had higher obesity. Among the patients who have similar age, duration of illness, type of nutrition and physical activity, there was no relation between the MetS and usage of AM and AP.
- Subjects
METABOLIC syndrome; ANTIPSYCHOTIC agents; SCHIZOPHRENIA; BODY mass index; CHLORPROMAZINE; OBESITY
- Publication
Klinik Psikofarmakoloji Bulteni, 2009, Vol 19, pS292
- ISSN
1017-7833
- Publication type
Article